Table 3.

Multivariable analysis for SNPs and prostate cancer outcomes

SNPNo. of patientsBiochemical recurrenceClinical metastasesProstate cancer–specific death
n = 351n = 146n = 91
HR95% CI*PHR95% CIPHR95% CIP
rs104865676351.291.00-1.650.0461.420.96-2.100.0831.10.66-1.820.7
rs49624166281.080.84-1.390.50.870.58-1.290.50.850.50-1.450.6
rs79205176311.531.17-2.010.0021.110.73-1.680.61.060.61-1.840.8
rs79313426321.030.80-1.320.82.011.35-3.000.00061.811.07-3.050.027
rs108964496491.010.79-1.2811.881.28-2.770.0011.831.10-3.040.021
rs27358396430.880.67-1.170.41.260.84-1.870.32.221.35-3.660.002
rs70084826170.850.66-1.090.190.870.59-1.280.510.60-1.651

NOTE: Each SNP is individually assessed in separate multivariable models, controlling for age at prostate cancer diagnosis, PSA at diagnosis, clinical stage, and biopsy Gleason grade. Shown are SNPs with univariate associations at P < 0.05 by the 2 df test.

  • ↵*The first P value shown for each SNP was determined by a 2 df test for a global difference across genotypes; the second P value shown was determined by a log-additive (linear trend) model.